|
ResMed Launches India Operations With Respicure Medsys
ResMed, a $3.5 billion US-based medical devices manufacturer, has announced
the launch of its marketing operations in India, through a partnership with a
local company Respicure Medisys.
The company plans to target the major metros and tier two cities like
Chandigarh, Jaipur, Lucknow and others in India, initially. The company's Asia
Pacific headquarters is based in Sydney, Australia.
ResMed is a leading medical device developer, manufacturer and marketer for
diagnosis and treatment of sleep Disordered Breathing (SDB) and non-invasive and
invasive ventilation products. SDB affects around 20 per cent of the adult world
population. The disease is equally widespread as asthma and diabetes but the
awareness is low and 90 per cent of affected people remain undiagnosed and
untreated, said a company release.
Paul Eisen, senior vice president and head of ResMed Asia Pacific Ltd., said,
"ResMed's leading edge technology in CPAP and mask solutions will now be
accessible to the Indian people through our partnership with local company
Respicure Medsys. And although we are well known for our sleep business, we
clearly believe that our ventilation product range will service the growing
number of Indian People that required both invasive and non-invasive
ventilation."
ResMed offers integrated solutions for sleep disordered breathing like
Continuous Positive Airway Pressure (CPAP), Automatic Positive Airway Pressure (APAP),
Bilevel and Adaptive Servo Ventilation Therapy. It also offers mask technology
and humidification options and curing devices ranging from Continuous Positive
Airway Pressure (CAPA) Devices, Autotitration Devices, Bilevel Devices, Nasal
Pillow Systems, Nasal Masks, Face Masks, Heated Humidifiers and Passive
Humidifiers.
Sources said the Asia Pacific operations contribute 10 per cent of the total
revenue of the company. ResMed is in the list of Fortune magazine's list of
America's 100 Fastest-Growing Companies. It has over 2,500 employees worldwide
and distributes to over 65 countries with direct offices and distribution
partners. In Asia Pacific Limited ResMed has offices in Australia, New Zealand,
Japan and Hong Kong, Singapore, India and China are the new offices opened this
year.
(Ref : Chronicle Pharmabiz dated August 10, 2006)
Baxter To Introduce Extraneal PD Solution
Baxter India Pvt. Ltd., the wholloy owned subsidiary of Baxter Healthcare
International Inc, US, is planning to introduce a peritoneal dialysis solution
(PD) product, Extraneal, in India soon.
The company has moved for approval from the authorities for the product using
Icodextrin, and is planning to launch the product within two months. The phase
four studies on the product will be conducted soon in India, according to Anders
Tranaeus, Vice President, Medical Affairs, Asia Pacific Region, Baxter
Healthcare International Inc.
Icodextrin is a replacement against glucose for long dwells in some End Stage
Renal Disease (ESRD) patients, helping to optimise fluid and solute removal with
reduced metabolic side effects. Extraneal, the first in the next generation of
technologically improved peritoneal dialysis solutions, has been under
distribution in various countries for the last 15 years.
"We were waiting for the right time to introduce the product. Our strategy is
to carry the product along with continuous education programmes for patients, as
our products are to be handled by the patients in their residence without the
help of a healthcare personnel," Sanjiv Navangul, Business Unit Director, Baxter
(India) Pvt. Ltd. told Pharmabiz.
The new product used a novel osmotic agent, a polymer of glucose, to remove
greater amounts of fluid over the long dwell period as compared to standard 1.5
percent and 2.5 percent dextrose solutions. The product will expand options for
effective fluid management, which is one of the principle goals for home based
peritoneal dialysis according to the officials.
The company may launch a couple of new products within the next ten years, at
the right time when it identifies unmet needs of Indian patients, according to
Anders. He said that around 1.5 lakh new patients suffer from ESRD every year in
India, in which only 20,000 are treated in one way or another. With the vision
to provide more awareness for the physicians, para medicals and patients and
better quality treatment with new products, the company also expects to
collaborate with the government for kidney disease prevention and care
programmes.
Offering the entire treatment course of peritoneal dialysis, the company
expects a 20 per cent growth in its turnover to reach Rs 250 crore, by the year
2006.
(Ref : Chronicle Pharmabiz dated August 17, 2006)
|
